Answers are grounded in this paper and cite their sources.
On April 16, 2025, the Stop TB Partnership’s Global Drug Facility (GDF) announced that the price of pretomanid, an antibiotic used in the WHO-recommended combination treatment regimen for drug-resistant tuberculosis, was reduced to US$169 per treatment regimen, a decrease of 25% from $224 in October, 2024. This reduction, combined with decreases in the price of other drug-resistant tuberculosis drugs—bedaquiline, linezolid, and moxifloxacin—in February, 2025, means the cost of the 6-month treatment course (known collectively as BPaLM) is now $310, a 47% reduction from $588 in December, 2022, when WHO first recommended this regimen.
No takes yet. Share an insight, caveat, or question.
Ed Holt (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: